Transmission, acute HIV-1 infection and the quest for strategies to prevent infection

Nature Medicine

Volumn 9, Issue 7, 2003, Pages 847-852

  Pope, Melissa ^a   Haase, Ashley T ^b  

^a POPULATION COUNCIL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACUTE DISEASE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION RISK; MEDICAL RESEARCH; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS TRANSMISSION;

ACUTE DISEASE; AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MENSTRUAL CYCLE; MUCOUS MEMBRANE; SEMEN; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0037625131     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0703-847     Document Type: Review

References (92)

1. World Health Organization (WHO). AIDS epidemic update: December 2002 (WHO, Geneva, 2002).
2. Annan, K.A. In Africa, AIDS has a woman's face. New York Times 29 December (2002), p.9.
3. Miller, C.J. et al. Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J. Virol. 63, 4277-4284 (1989).
4. Miller, C.J. et al. In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques. J. Virol. 72, 3248-3258 (1998).
5. + T cell demographics and dynamics in lymphatic tissues. Annu. Rev. Immunol. 17, 625-656 (1999).
6. Tenner-Racz, K. et al. HTLV-III/LAV viral antigens in lymph nodes of homosexual men with persistent generalized lymphadenopathy and AIDS. Am. J. Pathol. 123, 9-15 (1986).
7. Biberfeld, P. et al. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am. J. Pathol. 125, 436-442 (1986).
8. Pantaleo, G. et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88, 9838-9842 (1991).
9. Fox, C.H. et al. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J. Infect. Dis. 164, 1051-1057 (1993).
10. Pantaleo, G. et al. HIV infection is active and progressive in lymphoid tissue during the clinically Jatent stage of disease. Nature 362, 355-358 (1993).
11. Embretson, J. et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362, 359-362 (1993).
12. Schacker, T. et al. Rapid accumulation of HIV in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J. Infect. Dis. 181, 354-357 (2000).
13. Racz, P. et al. The spectrum of morphologic changes in lymph nodes from patients with AIDS or AIDS-related complex. Prog. Allergy 37, 81-181 (1985).
14. Cooper, D.A. et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1, 537-540 (1985).
15. Ho, D.D. et al. Primary human T-lymphotropic virus type III infection. Ann. Intern. Med. 103, 880-883 (1985).
16. Schacker, T.W., Hughes, J.P., Shea, T., Coombs, R.W. & Corey, L. Biological and virologic characteristics of primary HIV infection. Ann. Intern. Med. 128, 613-620 (1998).
17. Kahn, J.O. & Walker, B.D. Acute human immunodeficiency virus type 1 infection. N. Engl. J. Med. 339, 33-39 (1998).
18. Kinloch-de Loes, S. et al. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin. Infect. Dis. 17, 59-65 (1993).
19. Lavreys, L. et al. Primary human immunodeficiency virus type 1 infection: clinical manifestations among women in Monbasa, Kenya. Clin. Infect. Dis. 30, 486-490 (2000).
20. + T cells. Science286, 1353-1357 (1999).
21. Cavert, W. et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276, 960-964 (1997).
22. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
23. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
24. Little, S.J., McLean, A.R., Spina, C.A., Richman, D.D. & Havlir, D.V. Viral dynamics of acute HIV-1 infection. J. Exp. Med. 190, 841-850 (1999).
25. Koup, R.A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
26. + T cells. Nature 417, 95-98 (2002).
27. Lewis, J. et al. Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. J. Virol. 72, 8943-8951 (1998).
28. Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100, 4144-4149 (2003).
29. Goulder, P.J.R. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3, 212-217 (1997).
30. Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3, 205-211 (1997).
31. Price, D.A. et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94, 1890-1895 (1997).
32. Allen, T.M. et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nat. Med. 407, 386-390 (2000).
33. Chun, T.-W. et al. Quantitation of latent tissue reservoirs and total body load in HIV-1 infection. Nature 387, 183-188 (1997).
34. Haase, A.T. et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274, 985-989 (1996).
35. Persaud, D., Zhou, Y., Siliciano, J.M. & Siliciano, R.F. Latency in human immunodeficiency virus type 1 infection: no easy answers. J. Virol. 77, 1659-1665 (2003).
36. Heath, S.L., Tew, J.G., Szakal, A.K. & Burton, G.F. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377, 740-744 (1995).
37. Gray, R.H. et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357, 1149-1153 (2001).
38. Quinn, T.C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N. Engl. J. Med. 342, 921-929 (2000).
39. Deng, H.K. et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666 (1996).
40. Alkhatib, G. et al. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958 (1996).
41. Berger, E.A. et al. A new classification for HIV-1. Nature 391, 240 (1998).
42. Schuitemaker, H. et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66, 1354-1360 (1992).
43. Paxton, W.A. et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat. Med. 2, 412-417 (1996).
44. Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377 (1996).
45. Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856-1861 (1996).
46. Marx, P.A. et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2, 1084-1089 (1996).
47. Hu, J., Gardner, M.B. & Miller, C.J. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74, 6087-6095 (2000).
48. Martin, H.L. et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J. Infect. Dis. 180, 1863-1868 (1999).
49. Sweankambo, N. et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 350, 546-550 (1997).
50. Cohn, M.A. et al. Chronic inflammation with increased human immunodeficiency virus (HIV) RNA expression in the vaginal epithelium of HIV-infected Thai women. J. Infect. Dis. 184, 410-417 (2001).
51. Van Damme, L. et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet 360, 971-977 (2002).
52. Moss, G.B. et al. Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J. Infect. Dis. 164, 588-591 (1991).
53. Bomsel, M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 1, 42-47 (1997).
54. Bomsel, M. etal. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein diga or IgM. Immunity 9, 277-287 (1998).
55. Belec, L. et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis. 184, 1412-1422 (2001).
56. Veazey, R.S. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346 (2003).
57. + cells. Nat. Med. 2, 150-156 (2002).
58. Geijtenbeek, T.B.H. et al. DC-SIGN, a dendritic cell-specific HIV-1 binding protein that enhances trans-infection of T cells. Cell 100, 587-597 (2000).
59. Frank, I. & Pope, M. The enigma of dendritic cell-immunodeficiency virus interplay. Curr. Mol. Med. 2, 229-248 (2002).
60. Lee, B. et al. cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J. Virol. 75, 12028-12038 (2001).
61. Turville, S.G. et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat. Immunol. 3, 975-983 (2002).
62. Spira, A.I. et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183, 215-225 (1996).
63. + T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J. Virol. 76, 9868-9876 (2002).
64. Collins, K.B., Patterson, B.K., Naus, G.J., Landers, D.V. & Gupta, P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat. Med. 6, 475-479 (2000).
65. Granelli-Piperno, A., Delgado, E., Finkel, V., Paxton, W. & Steinman, R.M. Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J. Virol. 72, 2733-2737 (1998).
66. Reece, J.C. et al. HIV-1 selection by epidermal dendritic cells during transmission across human skin. J. Exp. Med. 187, 1623-1631 (1998).
67. McDonald, D. et al. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 300, 1295-1297 (2003).
68. Pope, M. et al. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell 78, 389-398 (1994).
69. + T cells. J. Exp. Med. 182, 2045-2056 (1995).
70. Schuitemaker, H. et al. Monocytotropic human immunodeficiency virus 1 (HIV-1) variants detectable in all stages of HIV infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J. Virol. 65, 356-363 (1991).
71. SM PBj: Evidence of macrophage-dependent viral amplification. Nat. Med. 4. 1401-1408 (1998).
72. Swingler, S. et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat. Med. 5, 997-1003 (1999).
73. Swingler, S. et al. HIV-1 Nef intersects the CD40L signaling pathway in macrophages to promote resting cell infection. Nature (in the press).
74. Messmer, D. et al. Endogenously expressed nef uncouples cytokine and chemokine production from membrane phenotypic maturation in dendritic cells. J. Immunol. 169, 4172-4182 (2002).
75. Sol-Foulon, N. et al. HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 16, 145-155 (2002).
76. Izmailova, E. et al. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat. Med. 9, 191-197 (2003).
77. Schwartz, E.J. et al. Effect of target cell availability on HIV-1 production in vitro. AIDS 16, 341-345 (2002).
78. DeBoer, R.J. & Perelson, A.S. Target cell limited and immune control models of HIV infection: a comparison. J. Theor. Biol. 190, 201-214 (1998).
79. Reilly, C., Schacker, T., Haase, A., Wietgrefe, S. & Krason, D. The clustering of infected SIV cells in lymphatic tissue. J. Am. Stat. Assn. 97, 943-954 (2002).
80. Reinhart, T.A. et al. Tracking members of the simian immunodeficiency virus deltaB670 quasispecies population in vivo at single-cell resolution. J. Virol. 72, 113-120 (1998).
81. + T cell depletion and viral replication in SIV infection. Science 280, 427-431 (1998).
82. + T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J. Infect. Dis. 187, 769-776 (2003).
83. + T cells, and AIDS. J. Virol. 71, 4016-4023 (1997).
84. Mothé, B.R. et al. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J. Virol. 76, 875-884 (2002).
85. Miller, C.J. et al. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J. Virol. 71, 1911-1921 (1997).
86. Amara, R.R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001).
87. Enose, Y. et al. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology 298, 206-316 (2002).
88. Crotty, S. et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J. Virol. 75, 7435-7452 (2001).
89. Johnson, R.P. et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73, 4952-4961 (1999).
90. Joag, S.V. et al. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J. Virol. 72, 9069-9078 (1998).
91. Zhu, T. et al. Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J. Virol. 77, 6108-6116 (2003).
92. + responses. J. Clin. Invest. 107, 341-349 (2001).